To evaluate the outcomes of PRP treatment in Achilles tendinopathy: An intriguing methodological problem

被引:7
作者
Abate, Michele [1 ]
Di Carlo, Luigi [1 ]
Salini, Vincenzo [2 ]
机构
[1] Univ G dAnnunzio, Dept Med & Sci Aging, Via Vestini 31, I-66013 Chieti, CH, Italy
[2] Osped San Raffaele, Div Orthoped & Traumatol, Milan, Italy
关键词
Achilles tendinopathy; Outcome; Platelet rich-plasma; Satisfaction; PLATELET-RICH PLASMA; INJECTION; ULTRASOUND; TRIALS;
D O I
10.1016/j.otsr.2020.102787
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Introduction: Assessing the outcomes of Platelet Rich Plasma (PRP) treatment in Achilles Tendinopathy (AT) may prove difficult due to several methodological reasons. For example, given that the simple mean of VISA-A score is just the result of positive, negative or null values, this may provide incomplete information, and therefore the size of individual changes can remain unknown. On the contrary, calculating the score changes in each subject after treatment would allow a more appropriate evaluation of the clinical results. However, this method has been applied only to few small-scale studies. Therefore we performed a retrospective study aiming to determine: (1) are the percentages of positive outcomes of the present research comparable to those of previous studies performed in different settings? (2) Is there a relationship between the size of increase of the clinical score and the patient satisfaction? Hypotheses: The percentages of positive outcomes of the present research are comparable to those of previous studies performed in different settings. Material and methods: This is a retrospective observational study. Eighty-four patients submitted to PRP treatment for mid-portion AT were enrolled. Pain and function were evaluated by means of VISA-A scale. Besides the mean, in each subject the pre- and post-treatment difference of VISA-A score was computed and the outcome was defined clinically no detectable, detectable and evident according to the increasing values of the score (0 to 9 points, 10 to 19, and >= 20 points change, respectively). The Likert's scale for the patients satisfaction was also used. Results: The mean VISA-A increased significantly after treatment (from 50.1 +/- 9.1 at baseline to 63.7 +/- 13.8 at 3 months (p = 0.00001) and 67.2 +/- 14.1 at 6 months (p = 0.00001)). At 3 and 6 months the subjects belonging to the prefixed categories were 15, 45, 24 and 19, 36, 29, respectively. Moreover, large discrepancies were observed between the size of increase of the clinical score and patients satisfaction, mainly for intermediate increases of the score. Discussion: The percentages of positive outcomes found in this study are slightly lower than those reported in literature. The different patients expectations about the efficacy of the therapy can explain the discrepancies between the size of increase of the clinical score and the individual satisfaction. In comparison to the simple mean, the individual changes of VISA-A score allow a proper evaluation of the outcomes. The research shows that discrepancies can be present in the percentage of positive clinical outcomes between different studies. The size of increase of the clinical score does not always match patient satisfaction. (C) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:5
相关论文
共 27 条
  • [1] Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial
    Bell, Kevin J.
    Fulcher, Mark L.
    Rowlands, David S.
    Kerse, Ngaire
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [2] Effect of High-Volume Injection, Platelet-Rich Plasma, and Sham Treatment in Chronic Midportion Achilles Tendinopathy A Randomized Double-Blinded Prospective Study
    Boesen, Anders Ploug
    Hansen, Rudi
    Boesen, Morten Ilum
    Malliaras, Peter
    Langberg, Henning
    [J]. AMERICAN JOURNAL OF SPORTS MEDICINE, 2017, 45 (09) : 2034 - 2043
  • [3] Connan E, 2010, ORTHOP TRAUMATOL-SUR, V96, P111, DOI [10.1016/j.otsr.2010.02.001, 10.1016/j.rcot.2010.02.014]
  • [4] Crescibene A, 2015, J BLOOD TRANSFUS, V2015
  • [5] Dallaudiere B, 2013, Diagn Interv Imaging, V94, P871, DOI 10.1016/j.diii.2013.05.010
  • [6] One-Year Follow-up of Platelet-Rich Plasma Treatment in Chronic Achilles Tendinopathy A Double-Blind Randomized Placebo-Controlled Trial
    de Jonge, Suzan
    de Vos, Robert J.
    Weir, Adam
    van Schie, Hans T. M.
    Bierma-Zeinstra, Sita M. A.
    Verhaar, Jan A. N.
    Weinans, Harrie
    Tol, Johannes L.
    [J]. AMERICAN JOURNAL OF SPORTS MEDICINE, 2011, 39 (08) : 1623 - 1629
  • [7] Platelet-Rich Plasma Injection for Chronic Achilles Tendinopathy A Randomized Controlled Trial
    de Vos, Robert J.
    Weir, Adam
    van Schie, Hans T. M.
    Bierma-Zeinstra, Sita M. A.
    Verhaar, Jan A. N.
    Weinans, Harrie
    Tol, Johannes L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (02): : 144 - 149
  • [8] Erroi D, 2017, MLTJ-MUSCLE LIGAMENT, V7, P98, DOI 10.11138/mltj/2017.7.1.098
  • [9] Ferrero G, 2012, J Ultrasound, V15, P260, DOI 10.1016/j.jus.2012.09.006
  • [10] Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: results at 4 years
    Filardo, Giuseppe
    Kon, Elizaveta
    Di Matteo, Berardo
    Di Martino, Alessandro
    Tesei, Giulia
    Pelotti, Patrizia
    Cenacchi, Annarita
    Marcacci, Maurilio
    [J]. BLOOD TRANSFUSION, 2014, 12 (04) : 533 - 540